MX1 and respiratory tract infectious disorder: In summary, there is a need for (1) assessing the diagnostic accuracy of MxA as a biomarker for viral childhood CAP; (2) new studies on clinical CAP etiology in children; (3) evaluating the antigen-based point-of-care test mariPOC; (4) evaluating a novel RPA-based point-of-care test developed at SciLifeLab; and (V) assessing long-term complications from CAP, including the risk of developing asthma and the risk for future respiratory infections.